

## Media Release

Zug, 3 January 2018

### **Delightful 2017 for HBM Healthcare Investments with 26% value increase of the NAV and 40% gain on the share price**

As at 31 December 2017, the net asset value per share (NAV) stood at CHF 162.07. Thus, HBM Healthcare Investments closes calendar year 2017 with a gratifying value increase of 26 percent at NAV level and by more than 40 percent to CHF 133.30 for the share price.

#### **Result for the 9 months of the current financial year 2017/2018**

For the first nine months of the current financial year 2017/2018, HBM Healthcare Investments expects a profit of over CHF 85 million, with an increase of 8 percent in NAV and a gain of 25 percent on the share price.

The two main contributors to the good result stem from the portfolio of private companies. The share price of Advanced Accelerator Applications (profit contribution of CHF 105 million for the financial year) has doubled since the beginning of the financial year due to the takeover bid by Novartis. AnaptysBio also made an impressive increase in value by contributing a profit of CHF 33 million. The company placed new shares in an IPO at a price of USD 15 per share in January 2017. Thanks to promising Phase 2a study data for a drug to treat dermatitis, the share price rose to more than USD 100 per share by the end of 2017. HBM Healthcare Investments originally invested USD 7 million in July 2015 in the then private company at USD 7.42 per share.

These figures are preliminary results based on the current status of work of the financial closing. The final results will be published with the quarterly report December 2017 on January 25, 2018.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

### Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

### HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)